SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)
Date: April 13, 2026 · CIK: 0001621221 · Accession: 0000000000-26-003674

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294912

Date
April 13, 2026
Author
Division of
Form
UPLOAD
Company
ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)

Letter

Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 Filed April 07, 2026 File No. 333-294912 Dear Gregory D. Gorgas:

April 13, 2026

Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Amanda I. Hawthorne, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 13, 2026

Gregory D. Gorgas
Chief Executive Officer
Artelo Biosciences, Inc.
505 Lomas Santa Fe, Suite 160
Solana Beach, CA 92075

 Re: Artelo Biosciences, Inc.
 Registration Statement on Form S-1
 Filed April 07, 2026
 File No. 333-294912
Dear Gregory D. Gorgas:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Amanda I. Hawthorne, Esq.
</TEXT>
</DOCUMENT>